A Phase 4 interventional study of Nilotinib in Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) and Acute Lymphoblastic Leukemia (ALL), sponsored by Novartis Pharmaceuticals. Completed at 33 sites in 16 countries. Per ClinicalTrials.gov, last updated 2024-02-08.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 33rd largest by enrollment, is one of 11 that started in 2013, is one of 12 in phase 4, and was the 38th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 11 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 36th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2013, is one of 13 in phase 4, and was the 48th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the treatment as judged by the investigator
This was a multi-center, open label, single-arm, phase IV study to better characterize the long-term safety of nilotinib in patients treated in Novartis-sponsored studies and who benefited from treatment with nilotinib.
Patients who were enrolled in Novartis-sponsored nilotinib studies, had benefitted from treatment with nilotinib and fulfilled all requirements in the parent study could be enrolled into the current roll-over study.
There was no sample size estimation carried out for this study.
Patients returned to the study center on a quarterly basis (12 weeks ± 1 week) for scheduled visit. Adverse Events (AEs) (non-serious and serious AEs), clinical benefit assessment by investigator and study medication dispensing information were collected.
The original protocol of the current roll-over study was designed to provide continuation of treatment with nilotinib for patients enrolled in nilotinib studies. Therefore, the original protocol did not require AEs (non-serious and serious AEs) to be collected into the clinical database and only required serious adverse events (SAEs) to be collected in the Novartis safety database throughout the study duration.
The scheduled visit frequency was annually.
However, feedback from health authorities stated that all AEs should be collected. To account for this, the protocol was amended in 2016 (Protocol amendment 3 (PA 3)), with the primary objective changed to assess long-term safety of nilotinib. Consequently, PA 3 started to require all AEs (non-serious and serious AEs) to be entered into the clinical database, in addition to the continued SAE collection into the Novartis safety database. At the same time, the scheduled visit frequency was increased from annually to quarterly, and the protocol was also amended to require an investigator assessment of clinical benefit for patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Patient is currently enrolled in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study receiving nilotinib and has fulfilled all their requirements in the parent study -Patient is currently benefiting from the treatment with nilotinib, as determined by the investigator -Patient has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements -Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures -Written obtained prior to enrolling in roll-over study
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
Drug: Nilotinib
Patients who were on nilotinib treatment in a Novartis-sponsored study (parent study) and were benefiting from nilotinib treatment met the criteria for enrolment into the CAMN107A2409 study and to receive continued nilotinib treatment. The starting dose of nilotinib in the CAMN107A2409 study should have been the same as the last dose administered in the parent study. After the starting dose, the dose of nilotinib was based on the investigator's judgement. The dose of nilotinib should have been ≤ 800 mg/day for adult patients, 230mg/m2 body surface area (BSA) and ≤ 800 mg/day for pediatric patients.
Also known as: AMN107
Number of Participants With Adverse Events and Serious Adverse Events
An Adverse Event (AE) is any untoward medical occurrence (eg any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Serious adverse event (SAE) case data were collected in the Safety Database. Adverse event (AE) data (both non-serious and serious) were collected in the Clinical database. Max. = Maximum Yrs = Years Approx. = Approximately eCRF = electronic Case Report Form Time = timeframe
Time frame: SAE case data were collected the entire study duration after first dose of study treatment up to a max. time of approx. 10 yrs. AEs (both non-serious and serious) were collected in the eCRF 3 yrs after study initiation up to a max. time of approx. 7 yrs.
Number of Participants With Clinical Benefit From Nilotinib
Number of patients (pts) with clinical benefit as assessed by investigator. Clinical benefit data were first collected 3 years after study initiation and up to a maximum timeframe of approx. 7 years and 3 months at a patient level (up to Week 528 total at the study level). Pts who discontinued in the first 3 years after study initiation didn't have any clinical benefit data collected. Pts who enrolled in the first 3 years after study initiation only had clinical benefit data collected starting at approx. the third year of the study until the end of the patient's participation in the study. Pts who enrolled after the first 3 years after study initiation had all clinical benefit data collected until the end of the patient's participation in the study. Data for the earlier time points are provided only for later enrolled pts. Data for the later time points are provided only for the earlier enrolled pts. The time point per patient was calculated from the date of first drug intake.
Time frame: Clinical benefit data were first collected 3 years after study initiation and are reported at baseline, Weeks 24, 48, 72, 96, 144, 192, 240, 288, 336, 384, 432, 480, and 528.
| Milestone | Nilotinib |
|---|---|
| Started | 57 |
| Completed | 20 |
| Not completed | 37 |
| Withdrew: Administrative problems | 1 |
| Withdrew: Patient/guardian decision | 1 |
| Withdrew: Patient withdrew consent | 2 |
| Withdrew: Physician decision | 4 |
| Withdrew: Disease progression | 24 |
| Withdrew: Adverse event | 5 |
An Adverse Event (AE) is any untoward medical occurrence (eg any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a clinical investigation participant after providing written informed consent for participation in the study. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product. Serious adverse event (SAE) case data were collected in the Safety Database. Adverse event (AE) data (both non-serious and serious) were collected in the Clinical database. Max. = Maximum Yrs = Years Approx. = Approximately eCRF = electronic Case Report Form Time = timeframe
| Participants | Nilotinib |
|---|---|
| Adverse Events - total | 29 |
| Adverse Events - Treatment-related adverse events | 15 |
| SAEs - total | 17 |
| SAEs - Treatment-related SAEs | 2 |
| AEs leading to discontinuation - total | 3 |
| AEs leading to discontinuation - Treatment-related AEs leading to discontinuation | 3 |
Number of patients (pts) with clinical benefit as assessed by investigator. Clinical benefit data were first collected 3 years after study initiation and up to a maximum timeframe of approx. 7 years and 3 months at a patient level (up to Week 528 total at the study level). Pts who discontinued in the first 3 years after study initiation didn't have any clinical benefit data collected. Pts who enrolled in the first 3 years after study initiation only had clinical benefit data collected starting at approx. the third year of the study until the end of the patient's participation in the study. Pts who enrolled after the first 3 years after study initiation had all clinical benefit data collected until the end of the patient's participation in the study. Data for the earlier time points are provided only for later enrolled pts. Data for the later time points are provided only for the earlier enrolled pts. The time point per patient was calculated from the date of first drug intake.
| Participants | Nilotinib |
|---|---|
| Patients with clinical benefit - Baseline | 15 |
| Patients with clinical benefit - Week 24 | 11 |
| Patients with clinical benefit - Week 48 | 17 |
| Patients with clinical benefit - Week 72 | 11 |
| Patients with clinical benefit - Week 96 | 19 |
| Patients with clinical benefit - Week144 | 23 |
| Patients with clinical benefit - Week 192 | 26 |
| Patients with clinical benefit - Week 240 | 20 |
| Patients with clinical benefit - Week 288 | 9 |
| Patients with clinical benefit - Week 336 | 9 |
| Patients with clinical benefit - Week 384 | 7 |
| Patients with clinical benefit - Week 432 | 6 |
| Patients with clinical benefit - Week 480 | 6 |
| Patients with clinical benefit - Week 528 | 4 |
Collected over Serious adverse event (SAE) case data were collected in the Safety Database the entire study duration after first dose of study treatment, up to a maximum timeframe of approx. 10 years. Adverse Event (AE) data (both non-serious and serious AEs) were collected in the Clinical Database 3 years after study initiation up to a maximum timeframe of approx. 7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | 0/57 (0%) | 17/57 (29.8%) | 20/57 (35.1%) |
| Event | Nilotinib |
|---|---|
| Myocardial infarctionCardiac disorders | 1/57 |
| Myocardial ischaemiaCardiac disorders | 1/57 |
| TachycardiaCardiac disorders | 1/57 |
| Abdominal painGastrointestinal disorders | 1/57 |
| Abdominal pain upperGastrointestinal disorders | 1/57 |
| Intestinal obstructionGastrointestinal disorders | 1/57 |
| MelaenaGastrointestinal disorders | 1/57 |
| Pancreatitis acuteGastrointestinal disorders | 1/57 |
| CholelithiasisHepatobiliary disorders | 1/57 |
| COVID-19Infections and infestations | 1/57 |
| Event | Nilotinib |
|---|---|
| HeadacheNervous system disorders | 5/57 |
| COVID-19Infections and infestations | 4/57 |
| MyalgiaMusculoskeletal and connective tissue disorders | 4/57 |
| AlopeciaSkin and subcutaneous tissue disorders | 4/57 |
| Abdominal pain upperGastrointestinal disorders | 3/57 |
| FatigueGeneral disorders | 3/57 |
| NasopharyngitisInfections and infestations | 3/57 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 3/57 |
| ParaesthesiaNervous system disorders | 3/57 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/57 |
| Age, Categorical(Participants) | Nilotinib |
|---|---|
| <=18 years | 7 |
| Between 18 and 65 years | 30 |
| >=65 years | 20 |
| Age, Continuous(years) | Nilotinib |
|---|---|
| Mean | 53.02 ± 19.278 |
| Sex: Female, Male(Participants) | Nilotinib |
|---|---|
| Female | 30 |
| Male | 27 |
| Race and Ethnicity Not Collected(Participants) | Nilotinib |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Mar 2013 to primary completion in Jul 2023, 123 months.
Results were first posted in Feb 2024, 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →